Compare · GH vs HUM
GH vs HUM
Side-by-side comparison of Guardant Health Inc. (GH) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GH and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.31B, about 2.1x GH ($22.44B).
- Over the past year, GH is up 205.1% and HUM is up 44.4% - GH leads by 160.6 points.
- HUM has been more active in the news (17 items in the past 4 weeks vs 12 for GH).
- Both have 25 recent analyst ratings on file.
- Company
- Guardant Health Inc.
- Humana Inc.
- Price
- $167.21-0.74%
- $385.34+0.07%
- Market cap
- $22.44B
- $46.31B
- 1M return
- +4.47%
- -1.79%
- 1Y return
- +205.07%
- +44.44%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 12
- 17
- Recent ratings
- 25
- 25
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest GH
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Hidalgo Medina Manuel sold $279,202 worth of shares (1,700 units at $164.24) and exercised 950 shares at a strike of $32.55, decreasing direct ownership by 14% to 4,556 units (SEC Form 4)
- Director Clark Ian T exercised 9,088 shares at a strike of $60.63 and sold $2,253,451 worth of shares (14,180 units at $158.92) (SEC Form 4)
- SEC Form 144 filed by Guardant Health Inc.
- SEC Form S-3ASR filed by Guardant Health Inc.
- SEC Form 10-Q filed by Guardant Health Inc.
- Guardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
- Guardant Health to Participate in Upcoming Investor Conferences
- Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
Latest HUM
- James P. Holland to Join Humana as Medicaid President
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
- Director Smith Paul John was granted 544 units of Humana Common (SEC Form 4)
- Director Crawford Frederick John was granted 544 units of Humana Common (SEC Form 4)
- Humana upgraded by Evercore ISI with a new price target
- Humana upgraded by Leerink Partners with a new price target
- Humana downgraded by Raymond James
- New insider Crawford Frederick John claimed ownership of 21 units of Humana Common (SEC Form 3)
- New insider Smith Paul John claimed no ownership of stock in the company (SEC Form 3)